Midwifery

ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix

Retrieved on: 
Monday, December 9, 2019
RTT, Gynaecology, Health, Medicine, Gynaecological neoplasia, Uterine fibroid, Menstrual cycle, Heavy menstrual bleeding, Midwifery, Linzagolix, Endometriosis, Draft:ObsEva SA

Additionally, significant improvement (p

Key Points: 
  • Additionally, significant improvement (p
  • We are extremely pleased with these results for linzagolix in our first phase 3 study in women with heavy menstrual bleeding due to uterine fibroids, said Dr. Ernest Loumaye, ObsEva CEO and Co-Founder.
  • We look forward to the results from our second pivotal study, PRIMROSE 1 conducted in the US, in Q2 2020.
  • Linzagolix is currently in late-stage clinical development for the treatment of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis.

Women's Fertility Product Scores Top Marks from TopConsumerReviews.com

Retrieved on: 
Monday, December 2, 2019
Fertility medicine, Human reproduction, Sexual reproduction, Midwifery, Women's health, Humans, Infertility, Fertility, Ovulation

Factors like weight, medical conditions, age, and even stress can affect all aspects of the process, from ovulation to implantation.

Key Points: 
  • Factors like weight, medical conditions, age, and even stress can affect all aspects of the process, from ovulation to implantation.
  • Because of their successful all-natural approach to Women's Fertility, we're pleased to give Fertile XX our highest recommendation in 2019."
  • To find out more about Fertile XX and other Women's Fertility Products, including reviews and comparison rankings, please visit the Women's Fertility category of TopConsumerReviews.com at https://www.topconsumerreviews.com/infertility-women/ .
  • From Women's Fertility to Baby Stores and Stress Relief, TopConsumerReviews.com delivers in-depth product evaluations in order to make purchasing decisions easier.

Medincell Receives $19 Million Grant for Its mdc-WWM Program

Retrieved on: 
Thursday, November 28, 2019
Professional services, Health, Other Health, Finance, General Health, Pharmaceutical, Biotechnology, Midwifery, Abortion, Medicine, Articles, Unsafe abortion, Maternal death, Health, Bill & Melinda Gates Foundation

The grant is structured in advanced installments to cover the costs that will be incurred by the project.

Key Points: 
  • The grant is structured in advanced installments to cover the costs that will be incurred by the project.
  • Depending on the options chosen and on the advancement of the program, up to $11.75 million could be raised over the next 12 months including a first tranche of $4.75 million to be paid immediately.
  • As a reminder, a previous grant of $3.5 million was awarded in November 2017 by the Gates Foundation to fund the formulation research phase.
  • An estimated 74 million women fall pregnant unintentionally every year leading to
    25 million unsafe abortions and 47,000 maternal deaths2.

Panorama Publication Demonstrates Utility of Measuring Individual Fetal Fractions in Twin Pregnancies

Retrieved on: 
Wednesday, November 27, 2019
Branches of biology, Human reproduction, Medicine, Zoology, Midwifery, Prenatal testing, Twin, Obstetrics, Natera, Pregnancy, Zygosity, Cell-free fetal DNA

When the fetal fractions are discrepant, the signal from the dominant twin obfuscates the signal from the other twin.

Key Points: 
  • When the fetal fractions are discrepant, the signal from the dominant twin obfuscates the signal from the other twin.
  • "The ability to accurately determine zygosity in twin pregnancies, and individual fetal fraction in dizygotic pregnancies, is a major advancement in the management of twin pregnancies," saidPaul Billings, M.D., Ph.D., Natera's Chief Medical Officer.
  • The test also screens twin pregnancies for zygosity, fetal sex of each baby, and identifies risk for more genetic conditions in twin pregnancies than any other NIPT.
  • Validation of a Single-Nucleotide Polymorphism-Based Non-Invasive Prenatal Test in Twin Gestations: Determination of Zygosity, Individual Fetal Sex, and Fetal Aneuploidy.

Prenatal Opioid Exposure May Alter Brain Function in Babies

Retrieved on: 
Monday, November 25, 2019
Midwifery, Morphine, Opioid, Prenatal development, Pain, Health, Birth defects of diethylstilbestrol

Exposure to opioids in utero is believed to have lasting consequences on brain development and behavior.

Key Points: 
  • Exposure to opioids in utero is believed to have lasting consequences on brain development and behavior.
  • According to the researchers, NAS requires prolonged hospital stays, monitoring and, in severe cases, additional treatment with opioids.
  • The study group included 16 full-term infants, including eight exposed to opioids prenatally and eight who were not exposed to prenatal opioids, or opioid naive.
  • Dr. Radhakrishnan said larger and long-term outcome studies are underway to better understand the functional brain changes in prenatal opioid exposure and their associated long-term developmental outcomes.

Sheila E. Busks On The Streets Of Pittsburgh to Raise Funds for Women's Health Research at Magee-Womens Research Institute while Headlining the Women who Rock Benefit Rock Concert

Retrieved on: 
Thursday, November 21, 2019
Geography of Pennsylvania, Midwifery, Population, Reproductive health, Pittsburgh, Women's health, PENNSYLVANIA

In May, Sheila took to the streets of Pittsburgh while headlining the Women who Rock Benefit Concert, to raise awareness for women's rights and raise funds for women's health research benefiting Magee-Womens Research Institute (MWRI).

Key Points: 
  • In May, Sheila took to the streets of Pittsburgh while headlining the Women who Rock Benefit Concert, to raise awareness for women's rights and raise funds for women's health research benefiting Magee-Womens Research Institute (MWRI).
  • Based in Pittsburgh, MWRI is the nation's largest research institute dedicated solely to women's health and reproductive biology.
  • Sheila E. headlined the 2019 Women who Rock Benefit Concert at Stage AE in Pittsburgh, which raised over $100,000 for women's health research, benefiting MWRI.
  • MWRI is the largest research institute in the U.S. devoted exclusively to women's health research and reproductive biology.

New Scientific Publication Shows Sera Prognostics Is Leader in Assessing Preterm Birth Risk

Retrieved on: 
Monday, November 18, 2019
General Health, Health, Other Health, Medical devices, Women's health, Midwifery, Neonatology, Human reproduction, Health, Childhood, Obstetrics, RTT, Preterm birth, Gestational age, Pregnancy, Prenatal development, Preterm Birth, the PreTRM, Sera Prognostics, Inc.

Sera Prognostics, Inc., (Sera or the Company), the leading health diagnostics company dedicated to improving the lives of women and babies through individualized prenatal care, today announced that a key scientific publication, Effects of Selective Exclusion of Patients on Preterm Birth Test Performance, authenticates Sera as the leading authority in using biomarkers to assess preterm birth risk.

Key Points: 
  • Sera Prognostics, Inc., (Sera or the Company), the leading health diagnostics company dedicated to improving the lives of women and babies through individualized prenatal care, today announced that a key scientific publication, Effects of Selective Exclusion of Patients on Preterm Birth Test Performance, authenticates Sera as the leading authority in using biomarkers to assess preterm birth risk.
  • To validate the actual performance of a premature birth prediction, the intended-use population must include patients delivering across the entire spectrum of gestational ages.
  • Sera Prognostics is the leading health diagnostics company dedicated to improving the lives of women and babies through individualized prenatal care.
  • Sera is developing innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy.

Nuvo Group Presents Positive Data Results For Remote Maternal-Fetal Heart Rate Monitoring At The American Heart Association Scientific Sessions 2019

Retrieved on: 
Saturday, November 16, 2019
Human reproduction, Fertility, Midwifery, Obstetrics, Medicine, RTT, Women's health, Health, Prenatal testing, Pregnancy, Fetus

PHILADELPHIA, Nov. 16, 2019 /PRNewswire/ -- Nuvo Group, an emerging leader in maternal-fetal health, today announced new clinical data for INVU, a pregnancy monitoring and management platform, at the American Heart Association Scientific Sessions 2019 in Philadelphia.

Key Points: 
  • PHILADELPHIA, Nov. 16, 2019 /PRNewswire/ -- Nuvo Group, an emerging leader in maternal-fetal health, today announced new clinical data for INVU, a pregnancy monitoring and management platform, at the American Heart Association Scientific Sessions 2019 in Philadelphia.
  • The scientific poster, "Non-Invasive, Remote, Self-Administered Acquisition of Fetal and Maternal ECG During Pregnancy," was presented today, Saturday, November 16, 2019 at 4:30 p.m.
  • "The pivotal study validates a unique tool which can accurately provide measures of fetal heart rate in a continuous, easy and readily accessible manner.
  • Nuvo Group is committed to serving providers and expectant mothers by advancing pregnancy care with new technology, tools, and practices.

Evofem Biosciences to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 13, 2019
Behavior, Sexual reproduction, Articles, Midwifery, Women's health, Population, Reproductive health, Sexual intercourse, Birth control, Sexually Transmitted Infections

To access the live and archived webcasts of either event, visit the Investors section of the Evofem Biosciences website at www.evofem.com .

Key Points: 
  • To access the live and archived webcasts of either event, visit the Investors section of the Evofem Biosciences website at www.evofem.com .
  • Evofem Biosciences, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health.
  • Evofem Biosciences aims to advance the lives of women by developing novel solutions, such as woman-controlled contraception and potential protection from certain sexually transmitted infections.
  • Evofem Biosciences does not undertake any duty to update any forward-looking statement except as required by law.

Myriad’s Prequel™ Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal Screening

Retrieved on: 
Monday, November 11, 2019
Branches of biology, Genetics, Medicine, Chromosomal abnormalities, Midwifery, Down syndrome, Intellectual disability, Syndromes affecting the heart, Prenatal development, Chromosome abnormality, Prenatal testing, Ravinder Dhallan

The key finding is that Prequel without a fetal-fraction threshold achieves high accuracy, while maintaining a low test-failure rate of one in 1000.

Key Points: 
  • The key finding is that Prequel without a fetal-fraction threshold achieves high accuracy, while maintaining a low test-failure rate of one in 1000.
  • The Prequel Prenatal Screen uses a whole genome sequencing approach to identify chromosomal abnormalities including trisomies 21, 18 and 13.
  • The Myriad Prequel Prenatal Screen is a noninvasive prenatal screen (NIPS) that uses cell-free DNA (cfDNA) to determine if a pregnancy is at an increased risk for chromosome abnormalities, such as Down syndrome.
  • The Prequel Prenatal Screen can be ordered with the Foresight Carrier Screen and offered to all women, including those with high body mass index, and ovum donor or a twin pregnancy.